Gout Clinical Trial
Official title:
Knowledge, Attitude and Practice Regarding Diagnosis and Management of Gout Among Clinicians in Nepal: A Report From Web-Based Survey
A web-based descriptive survey was conducted among doctors with regular interaction with gout patients. The questionnaire comprised of 38 multiple choice questions; 9 questions for demographic data, 8, 11 and 10 questions each for knowledge, attitude and practice, respectively. Simple descriptive statistics were used to describe the correct responses.
Objective To understand the knowledge, attitude and treatment practices of gout among doctors
who regularly interacted with gout patients.
Methodology Study population: Physicians (including practicing medical graduates,
post-graduates in internal medicine, family medicine) and orthopedic surgeons were selected
randomly from the list of data from the Nepal Medical Council registry. All internists with
valid email ID on the registry of the "society of internal medicine of Nepal" (SIMON) were
included. Also, a list of MBBS graduates, family medicine and orthopedic practitioners
working in the peripheral set-up of Nepal was obtained and a random selection with
computer-generated random number table based on council registration number was made for
enrollment into the survey. Estimating a response rate of 30%, a total of 1200 clinicians
were selected based on their council registration number for the invitation to participate in
the survey.
Survey instrument: A standardized questionnaire was designed by a 3-member committee of NRA
focusing on the areas of knowledge, attitude and practice of gout with 9 questions pertaining
to demographic parameters, 8 to knowledge about the disease, 11 to attitude and 10 to
practice behaviors [tables 1-4]. The questions were designed as multiple-choice questions
(MCQ) to be marked by the respondent. Few questions had the provision of selecting more than
1 options. Open- ended questions were avoided to save the time of the respondents and thus
reduce the attrition rates[10].
Procedure: An email containing a letter of invitation for participation was sent to each of
the selected participant. It mentioned why they were receiving the email, the objectives of
the survey, the assurance of anonymity and confidentiality and a total answering time of less
than 5 minutes for encouraging participation. A link to the Google-form was attached in the
mail itself and a mention was made on the implied consent for participation in clicking the
link. A reminder email was sent after 1 week to all irrespective of whether they had
responded earlier.
Platform: A web-based platform was chosen with the use of Google-forms which was compatible
and user friendly to both browser and mobile users and to both iOS and Android users.
Multiple entries from the same email link were blocked. Web-based platform was chosen over
email survey because it provides the ability to transfer survey responses directly into a
database, eliminating transcription errors and preventing survey alteration by the survey
respondent and most importantly maintaining confidentiality and anonymity of respondents[11].
The answers were collected anonymously in an excel sheet at the main server for analysis.
Statistical analysis: Simple descriptive statistics were used to describe the frequency or
correct responses. Chi-square test was performed to assess the difference in knowledge,
attitude, and practices between clinicians with different medical qualifications. Analysis
was done using SPSS version 21 (SPSS, Inc., Chicago, IL, USA).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04060173 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
|
Phase 1 | |
Not yet recruiting |
NCT06187519 -
UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
|
N/A | |
Completed |
NCT03635957 -
Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
|
Phase 4 | |
Completed |
NCT04966325 -
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
|
Early Phase 1 | |
Completed |
NCT03015948 -
A Single Dose Study of SHR4640 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT02855437 -
Novel Methods for Ascertainment of Gout Flares -A Pilot Study
|
N/A | |
Active, not recruiting |
NCT02702375 -
Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases
|
N/A | |
Completed |
NCT01407874 -
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
|
Phase 2 | |
Completed |
NCT00985127 -
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
|
Phase 2 | |
Completed |
NCT00995618 -
Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
|
Phase 2 | |
Terminated |
NCT04987294 -
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT03291782 -
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT03388515 -
A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT06189404 -
Effect of Tigulixostat on the Pharmacokinetics of Theophylline
|
Phase 1 | |
Enrolling by invitation |
NCT03336203 -
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
|
Phase 4 | |
Recruiting |
NCT05586958 -
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
|
Phase 3 | |
Recruiting |
NCT04047394 -
A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05507723 -
Tight Control of Gouty Arthritis Compared to Usual Care
|
N/A | |
Recruiting |
NCT06056570 -
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
|
Phase 1/Phase 2 | |
Completed |
NCT02557126 -
Study of URC102 to Assess the Safety and Efficacy in Gout Patients
|
Phase 2 |